FBIO Quote, Financials, Valuation and Earnings

Checkpoint Therapeutics has a net margin of -87.96% compared to Fortress Biotech's net margin of -16268.29%. Fortress Biotech's return on equity of -- beat Checkpoint Therapeutics's return on equity of --.

Fortress Biotech has a consensus price target of $15.33, signalling upside risk potential of 776.19%. On the other hand Checkpoint Therapeutics has an analysts' consensus of $4.33 which suggests that it could grow by 8.61%. Given that Fortress Biotech has higher upside potential than Checkpoint Therapeutics, analysts believe Fortress Biotech is more attractive than Checkpoint Therapeutics.

Fortress Biotech has a beta of 1.750, which suggesting that the stock is 74.992% more volatile than S&P 500. In comparison Checkpoint Therapeutics has a beta of 1.412, suggesting its more volatile than the S&P 500 by 41.242%.

Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Checkpoint Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -14.46% of its earnings as a dividend. Checkpoint Therapeutics pays out -- of its earnings as a dividend.

Fortress Biotech quarterly revenues are $14.6M, which are larger than Checkpoint Therapeutics quarterly revenues of $41K. Fortress Biotech's net income of -$12.9M is lower than Checkpoint Therapeutics's net income of -$9.7M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Checkpoint Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.34x versus -- for Checkpoint Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Journey Medical has a net margin of -87.96% compared to Fortress Biotech's net margin of -16.34%. Fortress Biotech's return on equity of -- beat Journey Medical's return on equity of -125.77%.

Fortress Biotech has a consensus price target of $15.33, signalling upside risk potential of 776.19%. On the other hand Journey Medical has an analysts' consensus of $10.00 which suggests that it could grow by 88.32%. Given that Fortress Biotech has higher upside potential than Journey Medical, analysts believe Fortress Biotech is more attractive than Journey Medical.

Fortress Biotech has a beta of 1.750, which suggesting that the stock is 74.992% more volatile than S&P 500. In comparison Journey Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Journey Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -14.46% of its earnings as a dividend. Journey Medical pays out -- of its earnings as a dividend.

Fortress Biotech quarterly revenues are $14.6M, which are smaller than Journey Medical quarterly revenues of $14.6M. Fortress Biotech's net income of -$12.9M is lower than Journey Medical's net income of -$2.4M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Journey Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.34x versus 1.83x for Journey Medical. Usually stocks with elevated PS ratios are considered overvalued.

Hepion Pharmaceuticals has a net margin of -87.96% compared to Fortress Biotech's net margin of --. Fortress Biotech's return on equity of -- beat Hepion Pharmaceuticals's return on equity of --.

Fortress Biotech has a consensus price target of $15.33, signalling upside risk potential of 776.19%. On the other hand Hepion Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 130334.78%. Given that Hepion Pharmaceuticals has higher upside potential than Fortress Biotech, analysts believe Hepion Pharmaceuticals is more attractive than Fortress Biotech.

Fortress Biotech has a beta of 1.750, which suggesting that the stock is 74.992% more volatile than S&P 500. In comparison Hepion Pharmaceuticals has a beta of 1.625, suggesting its more volatile than the S&P 500 by 62.537%.

Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hepion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -14.46% of its earnings as a dividend. Hepion Pharmaceuticals pays out -- of its earnings as a dividend.

Fortress Biotech quarterly revenues are $14.6M, which are larger than Hepion Pharmaceuticals quarterly revenues of --. Fortress Biotech's net income of -$12.9M is lower than Hepion Pharmaceuticals's net income of -$4.9M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Hepion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.34x versus -- for Hepion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Mustang Bio has a net margin of -87.96% compared to Fortress Biotech's net margin of --. Fortress Biotech's return on equity of -- beat Mustang Bio's return on equity of --.

Fortress Biotech has a consensus price target of $15.33, signalling upside risk potential of 776.19%. On the other hand Mustang Bio has an analysts' consensus of -- which suggests that it could grow by 6992.2%. Given that Mustang Bio has higher upside potential than Fortress Biotech, analysts believe Mustang Bio is more attractive than Fortress Biotech.

Fortress Biotech has a beta of 1.750, which suggesting that the stock is 74.992% more volatile than S&P 500. In comparison Mustang Bio has a beta of 1.817, suggesting its more volatile than the S&P 500 by 81.737%.

Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mustang Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -14.46% of its earnings as a dividend. Mustang Bio pays out -- of its earnings as a dividend.

Fortress Biotech quarterly revenues are $14.6M, which are larger than Mustang Bio quarterly revenues of --. Fortress Biotech's net income of -$12.9M is lower than Mustang Bio's net income of -$1.4M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Mustang Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.34x versus -- for Mustang Bio. Usually stocks with elevated PS ratios are considered overvalued.